Related Experiment Video

Updated: Oct 2, 2026

Production of Lentiviral Vectors for Transducing Cells from the Central Nervous System
08:46

Production of Lentiviral Vectors for Transducing Cells from the Central Nervous System

Published on: May 24, 2012

Lentiviral vectors for gene therapy of HIV-induced disease

R G Amado1, I S Y Chen

  • 1Department of Medicine, Division of Hematology/Oncology, UCLA School of Medicine, Los Angeles, CA 90095-1678, USA.

Current Topics in Microbiology and Immunology
|March 15, 2002
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Lentiviral Vector Preparation for Efficient Gene and MicroRNA Modulation of Peritoneal Cavity Tissue-Resident Macrophages In Vivo in Mice
06:33

Lentiviral Vector Preparation for Efficient Gene and MicroRNA Modulation of Peritoneal Cavity Tissue-Resident Macrophages In Vivo in Mice

Published on: February 16, 2024

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles
11:08

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles

Published on: April 8, 2012

Related Experiment Videos

Last Updated: Oct 2, 2026

Production of Lentiviral Vectors for Transducing Cells from the Central Nervous System
08:46

Production of Lentiviral Vectors for Transducing Cells from the Central Nervous System

Published on: May 24, 2012

Lentiviral Vector Preparation for Efficient Gene and MicroRNA Modulation of Peritoneal Cavity Tissue-Resident Macrophages In Vivo in Mice
06:33

Lentiviral Vector Preparation for Efficient Gene and MicroRNA Modulation of Peritoneal Cavity Tissue-Resident Macrophages In Vivo in Mice

Published on: February 16, 2024

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles
11:08

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles

Published on: April 8, 2012

Related Concept Videos

Gene Therapy01:22

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy01:22

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...

Articles linked to this work by shared authors, journal, and citation graph.

Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab.

British journal of cancer·2007

An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2007

Formaldehyde-treated, heat-inactivated virions with increased human immunodeficiency virus type 1 env can be used to induce high-titer neutralizing antibody responses.

Journal of virology·2005

A randomized, multicenter study of subcutaneous and intravenous darbepoetin alfa for the treatment of chemotherapy-induced anemia.

Annals of oncology : official journal of the European Society for Medical Oncology·2005

Induction of humoral immune responses following vaccination with envelope-containing, formaldehyde-treated, thermally inactivated human immunodeficiency virus type 1.

Journal of virology·2005

Low-dose trimetrexate glucuronate and protracted 5-fluorouracil infusion in previously untreated patients with advanced pancreatic cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2002

Resolution Failure in Multiple Sclerosis: Linking Lipid Mediators to Neuroinflammation and Disease Progression.

Current topics in microbiology and immunology·2026

Resolution Medicine: Steps to Uncovering the Specialized Pro-resolving Mediator Superfamily and Their Potent Functions in Resolving Inflammation.

Current topics in microbiology and immunology·2026

Dysregulated Resolution of Inflammation in Atherosclerosis: Mechanistic Insights and Therapeutic Opportunities.

Current topics in microbiology and immunology·2026

Resolution Pathways in the Context of Viral Infections.

Current topics in microbiology and immunology·2026

Stromal Niches Regulating Skin Immunity and Repair.

Current topics in microbiology and immunology·2026

Resolving Cancer: Specialized Pro-resolving Mediators as Host-Directed Regulators of Tumor Progression and Therapy Response.

Current topics in microbiology and immunology·2026

Systemic responses to intravenous rAAV administration in boys with Duchenne muscular dystrophy.

Frontiers in molecular medicine·2026

Multifunctional Cu2-xSe nanomaterials for cancer theranostics: recent advances, therapeutic mechanisms, and translational challenges.

Frontiers in chemistry·2026

Correction to "Type 2 Diabetes Mellitus: Molecular Pathogenesis and Therapeutic Interventions".

MedComm·2026

Recent advances in research on novel therapeutic mechanisms and strategies for exosome-based treatment of ischemic stroke.

Frontiers in pharmacology·2026

Aptamer-guided delivery of miR-126 suppresses glioblastoma stem-like cell invasion and tumor progression.

Molecular therapy. Nucleic acids·2026

From molecular correction to functional rescue: delivery, tissue state, and immunobiology as the principal constraints on dystrophin-restoring therapy in Duchenne muscular dystrophy.

Frontiers in pharmacology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us